Esketamine rapid antidepression combined with dexmedetomidine sleep modulation for patients with depression and insomnia
Muyan Zuo, Yaozu Li, John P Williams, Lina Sun, Yongxiang Li, Ruoguo Wang, Guoqiang Ren, Qinyan Xu, Jianxiong An
preprint DOI: 10.1101/2024.11.07.24316911 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational prospective study |
|---|---|
| Sample size | 105 |
| Population | Patients with depression combined with insomnia |
| Interventions | Esketamine Dexmedetomidine |
| Duration | Follow-up at baseline, 24 hours, 7 days, 14 days, 21 days, one month, two months, and three months |
| Measures | 17-item Hamilton Depression Scale (HAMD-17), Pittsburgh Sleep Quality Index (PSQI), functional magnetic resonance imaging (fMRI) |
| Topics | Depression Esketamine |
| Key findings | Esketamine combined with dexmedetomidine was associated with reduced depression symptoms from 24 hours to three months and with changes in spontaneous neural activity in frontal, limbic, and temporal regions two hours after treatment. The authors conclude that this combination is effective and safe for depression with insomnia, though the observational design limits causal inference. |
Abstract
Purpose: Depression combined with insomnia is a complex bidirectional relationship that is more difficult to treat versus a single disorder, and there is a lack of effective treatments available. In this study, we carried out a novel way to simultaneously intervene in depression combined with insomnia and examined functional magnetic resonance imaging (fMRI) to help further elucidate the mechanisms. Patients and
Methods: A total of 105 patients with depression and insomnia were included in this observational and prospective study. 17-item Hamilton Depression Scale (HAMD-17), Pittsburgh Sleep Quality Index (PSQI) were collected from medical records at baseline (T0), 24 hours (T1), 7 days (T2), 14 days (T3), 21 days (T4), one month (T5), two months (T6), three months (T7) follow-up. fMRI scans were performed at baseline and two hours after treatment.
Results: Compared with baseline, the symptoms of depression in T1-T7 were significantly reduced. At two hours after treatment, the left amygdala, the left hippocampus, the left superior temporal gyrus, the left anterior cingulate gyrus, and the left paracingulate gyrus showed a consistent reduction in spontaneous neural functional activity. In contrast, the right dorsolateral superior frontal gyrus, middle frontal gyrus, infraorbital frontal gyrus, middle orbital frontal gyrus and right caudate nucleus showed increased consistency of spontaneous neural function. No unanticipated safety issues were detected, and the rate of side effects was equivalent to those reported in RCTs.
Conclusion: Our findings support the efficacy and safety of esketamine combined with dexmedetomidine (Dex) in patients with depression and insomnia, which provides a new approach to clinical improvement of depression combined with insomnia.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.